/
IMNN
$1.80+$0.01 (+0.56%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$7.5M
4M shares
52-week range
$1.70 – $11.19
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-22.07
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $500.0K | $500.0K | $500.0K | $500.0K | $500.0K | $0 | $0 | $0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — |
| R&D | $11.9M | $13.1M | $11.3M | $10.6M | $11.7M | $11.3M | $11.6M | $7.8M |
| Operating income | −$21.1M | −$20.6M | −$18.5M | −$21.0M | −$24.9M | −$21.0M | −$19.1M | −$14.7M |
| EBITDA | −$21.2M | −$16.6M | −$21.3M | −$20.9M | −$31.7M | −$19.9M | −$17.9M | −$13.8M |
| Net income | −$11.9M | −$16.9M | −$21.5M | −$20.8M | −$35.9M | −$19.5M | −$18.6M | −$14.5M |
| Net margin | -2376.7% | -3370.3% | -4296.7% | -4153.9% | -7179.6% | — | — | — |
| EPS (diluted) | -132.23 | -151.01 | -131.51 | -748.77 | -65.55 | -28.14 | -21.10 | -6.83 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $4M | $-3.28 | $-3.93–$-2.85 | 2 |
| 2027 | $5M | $-2.15 | $-2.77–$-1.78 | 3 |
| 2028 | $12M | $-1.94 | $-2.70–$-1.46 | 3 |
| 2029 | $11M | $-2.03 | $-2.03–$-2.03 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$3.07
Price
$1.80
Implied upside
+71%
Peer comparison
Imunon, Inc. Common Stock
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.
www.imunon.com- Employees
- 20
- IPO / List date
- Jul 24, 1995
- HQ
- LAWRENCEVILLE, NJ
Held by traders on TradeandTell
No one on the platform currently holds IMNN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in IMNN as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-08-07 | 1.15-for-1 |
| 2025-07-25 | 1-for-15reverse |
| 2022-03-01 | 1-for-15reverse |
| 2017-05-30 | 1-for-14reverse |
| 2013-10-29 | 1-for-4.5reverse |
Recent trades on TradeandTell
No one on the platform has traded IMNN yet.
